Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Withdrawn 2Completed 2Terminated 1Recruiting 1Available 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 9Thoracic 2Head & Neck 2Genitourinary 2Other 1NET 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Neuroendocrine Tumors 46Neoplasms 8Carcinoid Tumor 7Neoplasm Metastasis 5Gastro-enteropancreatic neuroendocrine tumor 5Pancreatic Neoplasms 3Neuroectodermal Tumors, Primitive 3Gastrointestinal Neoplasms 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Neuroendocrine 3Adenoma, Islet Cell 3Thyroid Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Serotonin Syndrome 2Sarcoma 2Pheochromocytoma 2Paraganglioma 2Neuroblastoma 2Neoplasms by Site 2Digestive System Neoplasms 2Digestive System Diseases 2Cholangiocarcinoma 2Carcinoma, Islet Cell 2Carcinoma, Hepatocellular 2Brain Neoplasms 2Adrenal Gland Neoplasms 2von Hippel-Lindau Disease 1Vipoma 1

Interventions

Oxaliplatin 1Leucovorin 1Fluorouracil 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Insulinoma × NET × Clear all
NCT00227617 2023-05-22

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

University of California, San Francisco

Phase 2/3 Terminated
36 enrolled 14 charts
EndocrineNETThoracic

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡